Investigational drug · Phase 2
AZD4956
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumours.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AZD4956"
First trial start
2026
Mar 17, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD4956", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumours
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD4956" as an intervention, largest first.
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07446855 · 180 participants (planned) · Start Mar 17, 2026 · Primary completion Mar 29, 2030
Drug: AZD4956; Saruparib · For: Solid Tumours
Sites: New York, New York; Providence, Rhode Island; Houston, Texas · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumours
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
- ODM-212Phase 22 trials
Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer
- BMS-986517Phase 21 trial
Bristol Myers Squibb · Solid Tumours
- EP0089-101Phase 21 trial
Ellipses Pharma · Solid Cancers, Solid Tumours
- GSK5864399Phase 21 trial
GSK · Solid Tumours
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.